Search

Displaying results 2731 - 2740 of 10000 in total
  1. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects.

  2. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes. … Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to [iloperidone] in vivo.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor Antagonists
  3. Drug

    Taurochenodeoxycholic acid

    go.drugbank.com/drugs/DB08833
    Experimental

    As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to … Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    Fidanacogene elaparvovec is a liver-specific adeno-associated virus (AAV) vector containing a codon-optimized human coagulation FIX gene that was investigated as a potential treatment for hemophilia B. … Current available treatments include substitution therapy involving the intravenous administration of standard factor IX once a week for bleeding or as prophylaxis and 2–3 times a week for severe hemophilia

  5. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  6. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  7. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075].

  8. Drug

    Insulin glargine

    go.drugbank.com/drugs/DB00047
    ApprovedInvestigational

    As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glargine, to lower glucose levels in the blood. … Insulin glargine is also available as the biosimilar, or "follow-on" product, Basaglar in the US and as Abasaglar in the EU.

    Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/MLProducts: BASALOG 100 IU/mL, SOLUTION FOR INJECTION IN A VIAL, BASALOG ONE® SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100 IU/ML
  9. Target

    Activated CDC42 kinase 1

    go.drugbank.com/bio_entities/BE0000772
    TargetHumans

    Contributes to the control of AXL receptor levels. … Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin.

    Synonyms: Tyrosine kinase non-receptor protein 2
  10. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … [A177754] Butalbital has a low degree of selectivity and a narrow therapeutic index.